Ahmed Alahmad

Central Retinal Artery Occlusion (CRAO) is an ocular emergency that threatens vision when the central retinal artery, the retina’s source of arterial blood, becomes occluded. The occlusion – most commonly caused by an embolus or thrombus – is the cause of sudden, painless, and profound monocular visual loss. CRAO has been described as a “stroke of the eye” due to its sudden nature and ischemic presentation. On fundoscopy, the retina appears pale with a typical cherry-red macula spot, and the condition betrays the underlying retinal infarction. The disease mandates immediate medical attention because the window for proper treatment is short and prognosis of visual recovery in most instances is poor (1).

The pathophysiology of CRAO is a carbon copy of cerebral ischemic stroke, where thromboembolic events lead to precipitating vascular occlusion and resultant tissue damage. Risk factors include atherosclerosis, hypertension, diabetes, cardiac valve disease, and carotid artery stenosis (1). In the patients over 50 years, giant cell arteritis (GCA) needs to be excluded because it can result in arteritic CRAO and requires urgent corticosteroid therapy to prevent bilateral visual loss (2). CRAO patients also risk experiencing systemic cardiovascular events such as cerebral stroke and myocardial infarction and therefore a complete cardiovascular and stroke workup is necessary (1). Despite a variety of treatments proposed – such as ocular massage, anterior chamber paracentesis, and hyperbaric oxygen therapy – no widely accepted standard therapy is available (3).

Recent investigations have examined alternative therapies, most notably the use of prostaglandin E₁ (PGE₁) because of its vasodilatory and cytoprotective properties. A 2025 retrospective study published in Frontiers in Ophthalmology found that patients with CRAO treated with intravenous PGE₁ within 24 hours of developing symptoms had better visual outcomes compared with those who received standard treatment (1). The study did not see any adverse effects and found that baseline retinal thickness and visual acuity improvement were related and hypothesized that early treatment with PGE₁ can enhance retinal perfusion and reduce ischemic damage. These findings set a hopeful direction for future clinical trials and potential treatment protocols.

On the basis of these developments, the management of CRAO is shifting towards an increasingly stroke-centred model. American Academy of Ophthalmology recommendations now counsel immediate referral to stroke centres for acute CRAO presentations, with emphasis on timely systemic workup and optimization of risk factors (2). While definitive care remains unavailable, innovative therapies like PGE₁ and improved interdisciplinary coordination hold the key to maximizing results. Further investigation is required to establish evidence-based recommendations and identify which patients will most benefit from prompt treatment. CRAO remains an emergent condition where time is blind, and the identification of greater understanding and care could radically alter its bleak prognosis.

References

1. Dagra A, Lucke-Wold B, McGrath K, Mehkri I, Mehkri Y, Davidson CG, et al. Central Retinal Artery Occlusion: A Review of Pathophysiological Features and Management. Stroke: Vascular and Interventional Neurology. 2025; Available from: https://www.ahajournals.org/doi/pdf/10.1161/SVIN.123.000977
2. American Academy of Ophthalmology. Retinal and Ophthalmic Artery Occlusions. Guideline Central. 2025 Feb 7 [updated 2025 Jun 24]; Available from: https://www.guidelinecentral.com/guideline/10634/
3. Dobler E. Central Retinal Artery Occlusion. Geeky Medics. 2021 Feb 26 [updated 2025 Jan 3]; Available from: https://geekymedics.com/central-retinal-artery-occlusion